Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBI310 plus sintilimab in dMMR/MSI-H advanced colorectal cancer
CTR20192402Phase 2Terminated
- Sponsor
- Innovent Biologics
- Start
- Jan 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of IBI310, sintilimab in colorectal adenocarcinoma, sponsored by Innovent Biologics. Started Jan 2020; status: terminated.
02
Drugs
IBI310sintilimab
03
Conditions
colorectal adenocarcinoma
Beyond the preview
Go deeper on CTR20192402.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20192402.